Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study ; volume:7 ; number:4 ; day:16 ; month:11 ; year:2020 ; pages:1021-1035 ; date:12.2020
Rheumatology and therapy ; 7, Heft 4 (16.11.2020), 1021-1035, 12.2020
- Urheber
-
Smolen, Josef S.
Sebba, Anthony
Ruderman, Eric M.
Schulze-Koops, Hendrik
Sapin, Christophe
Gellett, Amanda M.
Sprabery, Aubrey Trevelin
Li, Lingnan
Torre, Inmaculada de la
Gallo, Gaia
Liu-Leage, Soyi
Pillai, Sreekumar
Reis, Paulo
Nash, Peter
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-020-00250-3
- URN
-
urn:nbn:de:101:1-2021010719263530389991
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Smolen, Josef S.
- Sebba, Anthony
- Ruderman, Eric M.
- Schulze-Koops, Hendrik
- Sapin, Christophe
- Gellett, Amanda M.
- Sprabery, Aubrey Trevelin
- Li, Lingnan
- Torre, Inmaculada de la
- Gallo, Gaia
- Liu-Leage, Soyi
- Pillai, Sreekumar
- Reis, Paulo
- Nash, Peter
- SpringerLink (Online service)
Ähnliche Objekte (12)
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
Economic impact of biologic utilization patterns in patients with psoriatic arthritis
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis